The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; Ipsen; MSD; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Pfizer (Inst); Roche (Inst)
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Jose Angel Arranz Arija
Honoraria - Astellas Pharma; BMS; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Eisai; Janssen-Cilag; Merck; MSD Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Janssen; Merck/Pfizer; MSD
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Janssen; Kissei Pharmaceutical; Kyorin; Kyowa Kirin International; Merck; MSD; Nippon Kayaku; Nippon Shinyaku; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Enrique Grande
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Eusa Pharma; EUSA Pharma; IPSEN; Janssen-Cilag; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Ipsen; Lilly; Merck; Pfizer; PharmaMar; Roche
Speakers' Bureau - Astellas Pharma; Eisai; Pfizer
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Pfizer; Roche
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Ono Pharmaceutical; Sanofi
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Boris Alekseev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Eisai; ICON Clinical Research; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Marina Mencinger
Consulting or Advisory Role - Astellas Pharma; Merck; Novartis; Pfizer; Roche
Speakers' Bureau - Astellas Pharma; MSD; Novartis; Pfizer; Roche; Sanofi
 
Kouji Izumi
Speakers' Bureau - AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD
Research Funding - AstraZeneca; AstraZeneca (Inst); Chugai/Roche; Chugai/Roche (Inst); MSD; MSD (Inst)
 
Javier Puente
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Pfizer; Roche
 
Jian-Ri Li
No Relationships to Disclose
 
Fabiola Bene-Tchaleu
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - F. Hoffmann LaRoche
 
Sanjeev Mariathasan
Employment - Genentech
 
Chooi Peng Lee
Employment - Roche
 
Sandrine Bernhard
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Maria De Santis
Honoraria - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; Exelixis/Ipsen; Ferring; Gilead Sciences; Immunomedics; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; MSD Oncology; Novartis; Orion; Pfizer; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen
Consulting or Advisory Role - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Ferring; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Roche; Roche/Genentech; Sanofi